Trelegy Ellipta 200 ug/1 (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 200 ug/1

Trelegy Ellipta 200 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Strength

200 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0893-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta 200 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is designed for long-term use and is not intended for immediate relief of sudden breathing problems.

Side Effects

Common effects of Trelegy Ellipta 200 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a fungal infection in the mouth. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Precautions & Warnings

Trelegy Ellipta 200 ug/1 should be used as directed by a healthcare provider. It is important to follow the proper inhalation technique to ensure effective delivery of the medication. Regular monitoring may be required, especially for individuals with a history of asthma or other respiratory conditions. Always store the inhaler in a clean, dry place.

Avoid Interactions

Trelegy Ellipta 200 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antifungal or antibiotic treatments. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other respiratory depressants should be used with caution.

Frequently Asked Questions

Trelegy Ellipta 200 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It helps manage symptoms such as wheezing, shortness of breath, and coughing.

Trelegy Ellipta 200 ug/1 is a powder inhaler designed for once-daily use. Follow the instructions provided by your healthcare provider and the product labeling for proper administration.

Common side effects may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a fungal infection in the mouth.

No, Trelegy Ellipta 200 ug/1 is not intended for immediate relief of sudden breathing problems. It is designed for long-term maintenance treatment of COPD.

Follow the proper inhalation technique and store the inhaler in a clean, dry place. Regular monitoring may be required, especially for individuals with a history of asthma or other respiratory conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.